Oriel Therapeutics, a developer of patented technology for drug delivery through inhalers, has closed on an undisclosed amount of Series C venture funding, Venture Wire reported Thursday.
Oriel Chief Executive Officer Paul Atkins told Venture Wire that the round was led by New Leaf Venture Partners. However he declined to disclose the amount of the funding or the identity of other investors.
New Leaf, which has offices in California and New York, recently closed on a new $450 million investment fund.
Oriel recently was awarded its fourth patent. The company is developing technology first developed at the University of North Carolina at Chapel Hill.
The company was founded in 2002 and through two rounds of funding had raised $5 million.